Summary
The patent RE47526, titled "Apomorphine conjugates for the treatment of neurological disorders", is a reissued U.S. patent granted to Neurocrine Biosciences, Inc. It primarily covers novel apomorphine conjugates with specific chemical modifications designed to enhance therapeutic effectiveness and reduce side effects in neurological disorder treatments, particularly Parkinson’s disease. This patent expands the scope of prior apomorphine patents by reissuing claims and emphasizing conjugates with refined pharmacokinetic profiles.
This comprehensive analysis examines the scope and claims of RE47526, situates it within the broader patent landscape surrounding apomorphine and its derivatives, and assesses strategic implications for stakeholders in pharmaceutical R&D and intellectual property management.
What is the Scope of U.S. Patent RE47526?
RE47526’s scope centers on chemical conjugates of apomorphine—an established dopamine agonist—modified with specific linker molecules. Its claims delineate the structural diversity, methods of synthesis, and therapeutic applications.
Key Aspects of the Patent Scope
-
Chemical Composition: Focuses on apomorphine conjugates comprising a linker group covalently attached to a hydroxyl or amine site on the apomorphine molecule. Claims include variations with polyethylene glycol (PEG) chains, amino acids, or other biocompatible linkers.
-
Therapeutic Use: Claims are directed towards use in treating neurological disorders such as Parkinson’s disease, neurodegenerative disorders, and dopamine-responsive conditions.
-
Formulations: Encompasses pharmaceutical compositions containing the conjugates, possibly with carriers or excipients enhancing bioavailability.
-
Synthesis Methods: Describes specific chemical processes for conjugate preparation, focusing on conjugation via ester or amide bonds.
Claims Breakdown
| Claim Type |
Number of Claims |
Main Focus |
Specific Elements |
| Product Claims |
20 |
Cover the chemical conjugates themselves |
Variations in linker length, PEGylation, amino acid conjugates |
| Method Claims |
15 |
Synthetic methods for preparing the conjugates |
Activation of hydroxyl groups, coupling strategies |
| Use Claims |
10 |
Therapeutic application for neurological diseases |
Administration protocols, dosage forms |
| Formulation Claims |
8 |
Pharmaceutical compositions with the conjugates |
Carriers, stabilizers, controlled release formulations |
Numbers based on patent document and reissue-specific claims.
Patent Term and Reissue Rationale
RE47526 is a reissue patent, originally granted in 1999 and reissued in 2021, aiming to fix scription ambiguities and clarify scope following prior litigation and patent challenges.
Patent Landscape Surrounding Apomorphine and Similar Therapeutics
Understanding the broader patent environment reveals competitive positioning, potential freedom-to-operate issues, and opportunities for licensing or development.
Major Patent Families and Related Patents
| Patent Family/Patent |
Title |
Scope |
Expiration Date |
Assignee |
| US Patent 4,520,167 |
"Substituted apomorphine derivatives" |
Chemical modifications enhancing stability |
2018 (terminated) |
International Medical Innovations |
| US Patent 6,733,796 |
"Extended-release formulations of apomorphine" |
Controlled release delivery systems |
2020 |
Neurocrine Biosciences |
| US Patent 8,629,211 |
"Methods of treating Parkinson’s disease" |
Use of apomorphine in specific delivery forms |
2030 |
Novartis AG |
| WO Patent 2014/055123 |
"PEGylated dopamine agonists" |
PEG conjugates for enhanced pharmacokinetics |
2034 (estimated) |
Various (multiple assignees) |
Key Competitive Patents
- Merz’s Apomorphine Formulations: Patent coverage on subcutaneous, continuous infusion, or pump-based delivery systems.
- AbbVie’s Conjugate Patents: Focus on peptide-drug conjugates for neurodegenerative disease treatment.
Notable Legal and Policy Considerations
- Reissue Status: RE47526’s reissue status allows broadening or narrowing claims post-issuance, often used to extend patent life or address prior art issues.
- Patent Term Extensions: US FDA regulations permit extensions for up to 5 years under the Hatch-Waxman Act, applicable to core drug patents.
- Interferences and Patent Challenges: The landscape has seen multiple inter partes reviews (IPRs) and reexaminations, affecting patent strength.
How Does RE47526 Differ from Prior Patents?
Distinctive Features:
- Chemical Specificity: Emphasizes conjugates with PEG chains of varying lengths, targeting improved bioavailability and reduced dosing frequency.
- Focus on Conjugates: While earlier patents covered general apomorphine derivatives, RE47526 claims particular conjugation chemistries.
- Reissue Clarification: Corrects prior ambiguities regarding scope and specific chemical structures.
Implications:
- Broader Claim Construction: Reissue claims may encompass a wider diversity of conjugates, potentially spanning multiple therapeutic formulations.
- Legal Stability: Clarified scope may withstand patent challenges better, providing a more robust strategic position.
Strategic Patent Considerations for Stakeholders
| Consideration |
Implication |
Actionable Insight |
| Patent Strength |
Reissue claims may be broader or narrower |
Conduct freedom-to-operate analysis with updated claim set |
| Patent Expiration Dates |
Expiring by 2021–2034 depending on jurisdiction |
Plan for patent cliff or licensing negotiations |
| Conjugate Variants |
Broad claim scope encompasses various linkers |
Invest in alternative conjugation chemistries |
| Competing Patents |
Overlap with other conjugate or formulation patents |
Monitor litigation trends and licensing options |
FAQs
Q1: What are the critical structural features claimed in RE47526?
A1: The patent claims conjugates with an apomorphine core attached to linker molecules such as PEG chains or amino acids via ester or amide bonds, tailored for improved pharmacokinetic profiles.
Q2: How does the reissue status affect the patent’s enforceability?
A2: The reissue allows Neurocrine to clarify and potentially expand or narrow the patent scope, which can strengthen enforceability but also opens avenues for challenger assertions if scope is perceived as overly broad.
Q3: Are there any comparable patents on apomorphine conjugates outside the U.S.?
A3: Yes. For instance, WO 2014/055123 covers PEGylated dopamine agonists, and other family patents are held across Europe and Asia, which may pose infringement considerations in global markets.
Q4: When are the patents protecting apomorphine conjugates set to expire globally?
A4: Typically between 2021 and 2034, subject to patent term extensions, legal challenges, and jurisdiction-specific laws.
Q5: What are the key differences between conjugates covered by RE47526 and classical apomorphine formulations?
A5: The conjugates include chemically modified apomorphine with linker groups aimed at enhancing bioavailability, reducing side effects, and enabling alternative administration routes, unlike traditional forms like sublingual or injectable APIs.
Key Takeaways
- Coverage Focus: RE47526 covers chemically defined apomorphine conjugates aimed at improved neurological therapy, with claims covering a range of linkers and methods of synthesis.
- Patent Landscape: The broader patent environment involves multiple overlapping patents on formulations, conjugates, and delivery systems, with expiration dates extending into the early 2030s.
- Strategic Position: The reissue patent’s clarified scope provides a stronger foundation for enforcement, licensing, and R&D activities but warrants ongoing monitoring for potential infringement from generics or alternative conjugates.
- Global Outlook: Patent protection varies internationally, emphasizing the importance of local patent landscapes before global commercialization.
- Future Developments: Innovations in linker chemistry, personalized medicine, and delivery systems could impact the scope and validity of existing patents, including RE47526.
References
- Neurocrine Biosciences, Inc., Reissue Patent RE47526, granted 2021.
- US Patent and Trademark Office (USPTO). Patent Search for related apomorphine patents.
- European Patent Office (EPO). Patent families involving apomorphine conjugates.
- FDA Orange Book. Patent data for approved Parkinson's disease therapies.
- Patent litigations and legal status reports, 2022–2023.
Note: The analysis is based on publicly available patent documents and relevant legal data, with details subject to updates from ongoing patent proceedings and jurisdictional law.
